Maze Therapeutics, Inc./$MAZE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Maze Therapeutics, Inc.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Ticker
$MAZE
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
125
ISIN
US5787841007
Website
MAZE Metrics
BasicAdvanced
$493M
33.57
$0.34
-
-
Price and volume
Market cap
$493M
52-week high
$14.40
52-week low
$6.71
Average daily volume
96K
Financial strength
Current ratio
16.099
Quick ratio
15.812
Long term debt to equity
7.241
Total debt to equity
8.841
Profitability
EBITDA (TTM)
53.23
Gross margin (TTM)
100.00%
Net profit margin (TTM)
31.01%
Operating margin (TTM)
29.97%
Effective tax rate (TTM)
2.21%
Revenue per employee (TTM)
$1,340,000
Management effectiveness
Return on equity (TTM)
34.38%
Valuation
Price to earnings (TTM)
33.566
Price to revenue (TTM)
0.603
Price to book
1.69
Price to tangible book (TTM)
1.69
Price to free cash flow (TTM)
1.47
Free cash flow yield (TTM)
68.03%
Free cash flow per share (TTM)
766.06%
Growth
Earnings per share change (TTM)
-100.71%
Bulls say / Bears say
Maze Therapeutics successfully raised approximately $140 million in gross proceeds through an upsized IPO in February 2025, providing a cash runway into the second half of 2027, which supports the advancement of its clinical programs. (Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights)
The company initiated a Phase 2 clinical trial for MZE829, an oral APOL1 inhibitor targeting APOL1 kidney disease, with initial data expected in the first quarter of 2026, indicating progress in its pipeline. (Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights)
Analysts from JPMorgan Chase & Co. initiated coverage on Maze Therapeutics with an 'overweight' rating and a $30.00 price target, reflecting confidence in the company's growth potential. (Maze Therapeutics (NASDAQ:MAZE) Now Covered by JPMorgan Chase & Co.)
The U.S. Federal Trade Commission filed a complaint seeking to block Maze Therapeutics' license agreement with Sanofi for MZE001, potentially delaying or hindering the program's progress. (Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001)
Despite positive developments, Maze Therapeutics reported a net loss for the fourth quarter and full year of 2024, which may raise concerns about its financial sustainability. (Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights)
The company's stock price has experienced volatility, with a 52-week range between $10.08 and $17.00, which may indicate market uncertainty regarding its future performance. (Maze Therapeutics (NASDAQ:MAZE) Now Covered by JPMorgan Chase & Co.)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
MAZE News
AllArticlesVideos
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
GlobeNewsWire·3 weeks ago
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
GlobeNewsWire·1 month ago
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Maze Therapeutics, Inc. stock?
Maze Therapeutics, Inc. (MAZE) has a market cap of $493M as of June 20, 2025.
What is the P/E ratio for Maze Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Maze Therapeutics, Inc. (MAZE) stock is 33.57 as of June 20, 2025.
Does Maze Therapeutics, Inc. stock pay dividends?
No, Maze Therapeutics, Inc. (MAZE) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Maze Therapeutics, Inc. dividend payment date?
Maze Therapeutics, Inc. (MAZE) stock does not pay dividends to its shareholders.
What is the beta indicator for Maze Therapeutics, Inc.?
Maze Therapeutics, Inc. (MAZE) does not currently have a Beta indicator.